3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow pexelizumab: new trials by email Literature Review of pexelizumab trials Research Report on pexelizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II) pexelizumab in conjunction with CABG - Coronary Artery Disease | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 4000 | 2004-07-01 | 2018-02-22 |
| Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI) Pexelizumab, Placebo infusion - Acute Myocardial Infarction | Phase 3 | Completed | Procter and Gamble | 5745 | 2004-04-01 | 2023-11-18 |
| Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass pexelizumab - Cardio-pulmonary Bypass, Coronary Artery Bypass Graft | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 3000 | 2002-01-01 | 2017-02-23 |
Alexion Pharmaceuticals, Inc. (2) · Procter and Gamble (1)
United States (3) · Canada (2) · France (2) · Germany (2) · Netherlands (2) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · Italy (1) · New Zealand (1) · Poland (1) · Portugal (1) · Spain (1)
Edward Verrier, MD (1) · Peter X Adams, MD (1) · Thomas G Todaro, MD, JD, FACC (1)
PMID 17200474, PMID 18779444, PMID 19389560, PMID 19853693, PMID 20089518, PMID 20129531, PMID 20435202, PMID 20501476, PMID 20880552, PMID 21304097, PMID 22589297, PMID 22795281, PMID 22814783, PMID 23351826, PMID 23453104, PMID 23549644, PMID 24176448